Vivani Medical, INC

Vivani Medical, Inc. has released a Form 8-K filing containing an updated slide presentation for the investment community.

Vivani Medical has successfully dosed all participants in its Phase 1 SLIM-1 trial for NPM-139, a long-acting semaglutide implant.

Vivani Medical announced an updated timeline for its SLIM-1 first dosing, now expected in August 2026, during a presentation at the Emerging Growth Conference.

Vivani Medical, Inc. announced a definitive agreement to merge its subsidiary Cortigent, Inc. with ClearOne, Inc., creating a combined entity with a focus on future growth.

Vivani Medical's 8-K filing details the approval of an amended stock incentive plan and regulatory clearance for a Phase 1 obesity drug trial.

Vivani Medical, Inc. announced its participation in the Jefferies Global Healthcare Conference on June 4, 2026, presenting a slide deck detailing its current status.

Vivani Medical, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued operating losses and a need for further financing, while also announcing progress on clinical trials and a proposed merger for its Cortigent subsidiary.

Vivani Medical reports Q1 2026 results, detailing progress in its Biopharm Division, continued operational expenses, and strategic considerations for its Cortigent subsidiary.

Vivani Medical reported increased net losses and significant cash burn in Q3 2025, while securing new capital and advancing its lead GLP-1 implant program, NPM-139, towards clinical trials in 2026.

Vivani Medical reported increased net losses in Q2 2025, while advancing its GLP-1 implant programs and progressing with the spin-off of its neurostimulation division.

Vivani Medical announces Q1 2025 financial results, highlighting ongoing clinical trial progress and strategic shifts in focus.

Vivani Medical's Q3 2024 report highlights progress in its GLP-1 implant program, including a redesigned clinical trial and positive preclinical data, while also showing a net loss for the quarter.

Vivani Medical, Inc. reported a net loss of $26.6 million in 2025 while advancing its NanoPortal GLP-1 implant programs and securing significant capital.

Vivani Medical's 10-K filing highlights the company's focus on its obesity portfolio, progress in clinical trials, and financial activities including securities offerings and a potential Cortigent spin-off.

Vivani Medical shifts focus to obesity treatments, showcasing promising preclinical results for its NPM-115 implant.

Donald Dwyer, Chief Business Officer of Vivani Medical, Inc., reported multiple transactions in common stock on July 28, 2026.

Lisa Ellen Porter, Chief Medical Officer of Vivani Medical, Inc., reported multiple transactions in common stock on July 28, 2026.

Anthony Baldor, Chief Financial Officer of Vivani Medical, Inc., reported multiple transactions in common stock on July 28, 2026.

Truc Le, Chief Operations Officer of Vivani Medical, Inc., reported multiple transactions in common stock on July 28, 2026.

Adam Mendelsohn, Chief Executive Officer and a Director of Vivani Medical, Inc., reported multiple transactions in common stock on July 28, 2026.

Daniel Bradbury, a Director of Vivani Medical, Inc., received 7,965 shares of common stock on July 27, 2026.

Vivani Medical amends its definitive proxy statement to correct scrivener's errors in dates and compensation information, setting the Annual Meeting for June 24, 2025.

Vivani Medical, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Vivani Medical, Inc. invites stockholders to its 2025 Annual Meeting on June 24, 2025, to vote on director elections, auditor ratification, and executive compensation.

Vivani Medical will hold its annual stockholders meeting on June 27, 2024, to elect directors, ratify the appointment of an accounting firm, and conduct an advisory vote on executive compensation.

Vivani Medical, Inc. is set to hold its 2024 Annual Meeting of Stockholders virtually on June 27, 2024, to vote on the election of directors, ratification of the independent auditor, and executive compensation.

Gregg Williams and associated entities report beneficial ownership of 47.1% of Vivani Medical, Inc. common stock, totaling over 43.2 million shares.